
The PSMA PET radiopharmaceutical 64Cu-SAR-bisPSMA, which previously garnered two FDA fast track designations, more than doubled the detection of PCa lesions in comparison to 68Ga-PSMA-11 in the phase II Co-PSMA trial.
Catch up on the most well-viewed prostate imaging content from 2023.
As we come to the end of 2023, we take a look back at the most well-read prostate imaging content with topics ranging from emerging PSMA PET radiotracers to prostate artery embolization for men with an enlarged prostate. Review the slideshow below to see highlighted prostate imaging content from the past year.





